Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients

F. van Delft; E. Koffijberg; V. Retel; M. Schuurbiers; H. van Rossum; M. van den Heuvel; M. IJzerman

doi:10.1016/j.jval.2020.08.416

Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients

F. van Delft
, E. Koffijberg
, V. Retel
, M. Schuurbiers
, H. van Rossum
, M. van den Heuvel
, M. IJzerman

Research output: Contribution to journal › Article › Academic

72 Downloads (Pure)

Abstract

Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.

Original language	English
Article number	PCN279
Pages (from-to)	S472-S472
Journal	Value in health
Volume	23
Issue number	Suppl. 2
DOIs	https://doi.org/10.1016/j.jval.2020.08.416
Publication status	Published - Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

22/4 OA procedure

Access to Document

10.1016/j.jval.2020.08.416Licence: Elsevier licence

Van-delft-2020-Pcn-comparing-methods-of-longitudinFinal published version, 385 KBLicence: Taverne

Cite this

@article{9b9a217f8e1c445a9e8030fcb7f31687,

title = "Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients",

abstract = " Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.",

keywords = "22/4 OA procedure",

author = "\{van Delft\}, F. and E. Koffijberg and V. Retel and M. Schuurbiers and \{van Rossum\}, H. and \{van den Heuvel\}, M. and M. IJzerman",

year = "2020",

month = dec,

doi = "10.1016/j.jval.2020.08.416",

language = "English",

volume = "23",

pages = "S472--S472",

journal = "Value in health",

issn = "1098-3015",

publisher = "Elsevier",

number = "Suppl. 2",

}

TY - JOUR

T1 - Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients

AU - van Delft, F.

AU - Koffijberg, E.

AU - Retel, V.

AU - Schuurbiers, M.

AU - van Rossum, H.

AU - van den Heuvel, M.

AU - IJzerman, M.

PY - 2020/12

Y1 - 2020/12

N2 - Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.

AB - Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.

KW - 22/4 OA procedure

U2 - 10.1016/j.jval.2020.08.416

DO - 10.1016/j.jval.2020.08.416

M3 - Article

SN - 1098-3015

VL - 23

SP - S472-S472

JO - Value in health

JF - Value in health

IS - Suppl. 2

M1 - PCN279

ER -

Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this